PMID- 22170292
OWN - NLM
STAT- MEDLINE
DCOM- 20120503
LR  - 20181201
IS  - 1865-8652 (Electronic)
IS  - 0741-238X (Linking)
VI  - 28
IP  - 12
DP  - 2011 Dec
TI  - The management of patients with atrial fibrillation and dronedarone's place in 
      therapy.
PG  - 1059-77
LID - 10.1007/s12325-011-0086-1 [doi]
AB  - The pharmacologic management of atrial fibrillation (AF) includes rate and rhythm 
      control strategies. Antiarrhythmic agents (eg, amiodarone, flecainide, and 
      propafenone) are limited by serious toxicities (including proarrhythmic effects 
      and pulmonary toxicity), which may lead to a reduced net clinical efficacy of 
      rhythm control strategies. Dronedarone, a new antiarrhythmic agent, is effective 
      in the maintenance of sinus rhythm. Dronedarone has also been shown to reduce 
      ventricular rate and the incidence of hospitalization due to cardiovascular 
      events. Dronedarone is recommended by the 2011 American College of Cardiology 
      Foundation/American Heart Association/Heart Rhythm Society guidelines update for 
      the management of AF patients with no or minimal heart disease, coronary artery 
      disease, and hypertension with no left ventricular hypertrophy. Dronedarone is 
      contraindicated in patients with New York Heart Association (NYHA) class IV heart 
      failure or NYHA class II-III heart failure with a recent decompensation requiring 
      hospitalization or referral to a specialized heart failure clinic.
FAU - Cohen, Marc
AU  - Cohen M
AD  - Cardiac Cath Laboratory, Newark Beth Israel Medical Center, NJ 07112, USA. 
      marcohen@barnabashealth.org
FAU - Boiangiu, Catalin
AU  - Boiangiu C
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20111212
PL  - United States
TA  - Adv Ther
JT  - Advances in therapy
JID - 8611864
RN  - 0 (Anti-Arrhythmia Agents)
RN  - 0 (Anticoagulants)
RN  - JQZ1L091Y2 (Dronedarone)
RN  - N3RQ532IUT (Amiodarone)
MH  - Age Factors
MH  - Amiodarone/administration & dosage/adverse effects/*analogs & 
      derivatives/therapeutic use
MH  - Anti-Arrhythmia Agents/administration & dosage/adverse effects/*therapeutic use
MH  - Anticoagulants/therapeutic use
MH  - Atrial Fibrillation/complications/*drug therapy/*physiopathology
MH  - Cardiovascular Diseases/complications
MH  - Clinical Trials as Topic
MH  - Dronedarone
MH  - Heart Rate/drug effects
MH  - Humans
MH  - Practice Guidelines as Topic
MH  - Risk Factors
MH  - Sex Factors
EDAT- 2011/12/16 06:00
MHDA- 2012/05/04 06:00
CRDT- 2011/12/16 06:00
PHST- 2011/09/22 00:00 [received]
PHST- 2011/12/16 06:00 [entrez]
PHST- 2011/12/16 06:00 [pubmed]
PHST- 2012/05/04 06:00 [medline]
AID - 10.1007/s12325-011-0086-1 [doi]
PST - ppublish
SO  - Adv Ther. 2011 Dec;28(12):1059-77. doi: 10.1007/s12325-011-0086-1. Epub 2011 Dec 
      12.